Rehospitalisations for respiratory disease and respiratory syncytial virus infection in preterm infants of 29–36 weeks gestational age

This publication has 21 references indexed in Scilit:

• Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease
  The Journal of Pediatrics, 2003
• Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort
  Archives of Disease in Childhood, 2000
• Hospitalisation for RSV infection in ex-preterm infants---implications for use of RSV immune globulin
  Archives of Disease in Childhood, 2000
• Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study
  The Pediatric Infectious Disease Journal, 2000
• Stellungnahme der Deutschen Gesellschaft für Pädiatrische Infektiologie zur Prophylaxe von RSV-Erkrankungen durch Immunglobuline
  Klinische Padiatrie, 1999
• Prevention of Respiratory Syncytial Virus Infections: Indications for the Use of Palivizumab and Update on the Use of RSV-IGIV
  Pediatrics, 1998
• Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants
  Pediatrics, 1998
• Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-Risk Infants and Young Children
  New England Journal of Medicine, 1993
• MORBIDITY OF VERY LOW BIRTHWEIGHT INFANTS AT CORRECTED AGE OF TWO YEARS IN A GEOGRAPHICALLY DEFINED POPULATION
  The Lancet, 1989
• IDIOPATHIC RESPIRATORY DISTRESS SYNDROME. RECURRENT RESPIRATORY ILLNESS IN SURVIVORS
  Survey of Anesthesiology, 1973